Drug Profile
Research programme: antibacterials - Amoebics
Alternative Names: antibody-protein therapeutics -Amoebics; VenFcLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amoebics
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in United Kingdom
- 16 Apr 2007 This programme is still in active development
- 25 Jan 2006 Preclinical trials in Staphylococcal infections in United Kingdom (unspecified route)